In the coming weeks we will be providing short profiles of selected companies presenting at the 7th Annual OneMedForum in San Francisco on January 13th and the 14th. Our goal is to identify the most promising investment opportunities in emerging growth companies. Featured firms are those our analysts believe have significant upside potential and typically backed by respected investors. Learn more about the firms by visiting their profile at OneMedPlace. For more information about the 7th Annual OneMedForum please visit www.onemedconferences.com for the latest conference updates.
The OneMedPlace Team
OneMedForum announced today that it has assembled two panels featuring early entrants in the emerging areas of crowdfunding and online investment banking in healthcare. Panelists will offer insights on their experiences thus far, along with their outlook on this new approach to funding. The sessions will be held on Monday, January 13th, and Tuesday, the 14th, during the 7th Annual OneMedForum at the Westin San Francisco Market Street.
“We’re excited to get insights from the leading Portals as well as those providing the infrastructure for this emerging area,” said Brett
Regenesis Biomedical’s Provant Therapy System is FDA approved for the palliative treatment of post-operative pain and edema in superficial soft tissue. Post surgery, many tissues may be moved around or inflamed, but Provant helps reduce the pain by inducing endogenous opioids. This prescription only device exposes tissue to electromagnetic energy using an optimized energy pulse.
Preliminary data in preclinical models of severe complex wounds suggests that human VSELs™ (very small embryonic like stem cells) accelerates wound healing. NeoStem hopes to advance into early clinical studies to assess therapeutic potential of VSEL technology.
Early results for the new flu drug FluCide® found to be safe in a non-GLP small animal safety/ toxicology study. These preliminary results support the company’s earlier reports of the FluCide® drug being effective in animal models of different influenza A virus strains. NanoViricides is also developing drugs against HIV/AIDS (HivCide™-I), Dengue (DengueCide™-I), and External Eye Viral disease (EKC-Cide™-I), amongst other viral diseases.
STR has started a clinical trial in Europe for its ACL device and has successfully implanted the device in 7 patients as of October 2013. Their device utilizes a synthetic scaffold that regenerates the entire ligament tissue resulting in better chances of full recovery.
Profound’s unique device for Prostate cancer treatment is currently in Phase I clinical trials in Europe and Canada. Profound has also received FDA approval to conduct clinical trials in U.S that will begin soon in 2013. The company is on fast track to begin commercialization in Europe by 2015.
NEW YORK, Oct. 15, 2013 – OneMedForum announced today that a major theme of its 7th annual healthcare investing conference will be to provide investors with an outlook about how the healthcare system will function post-Obamacare. Moreover, it will also address the new financing opportunities created by the JOBS Act and feature innovatively growing companies that are best positioned to succeed in this new environment.
OneMedPlace is a research and media company that searches the world for the most promising companies and technologies and provides a media platform to help them succeed. Learn More Register Here
For sponsorship opportunities, our sponsorship manager at email@example.com
For editorial inquiries, please contact our editor at firstname.lastname@example.org
or call 212-734-1008.
Follow our latest news and videos on Twitter